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bjectives We conducted this study to assess the prevalence and determinants of subclinical
hrombus after sirolimus-eluting stent (SES) implantation.
ackground Angioscopic analyses have demonstrated the presence of thrombus is more common
han the clinical incidence of SES thrombosis.
ethods Fifty-three patients (53 lesions) underwent 6-month follow-up optical coherence tomogra-
hy. A stent eccentricity index ([SEI] minimum/maximum stent diameter) was determined in each
ross section. To evaluate unevenness of neointimal thickness, a neointimal unevenness score ([NUS]
aximum neointimal thickness in the cross section/average neointimal thickness of the same cross
ection) was calculated for each cross section. Average SEI and NUS were calculated for each stent.
ajor adverse cardiac events were deﬁned as a composite of death, myocardial infarction, and
arget vessel revascularization.
esults Fourteen cases of thrombus (26%) were detected by optical coherence tomography
thrombus: n  14 vs. nonthrombus: n  39). The percentage of thrombus was associated with
onger stents (36.4  20.2 mm vs. 25.1  9.8 mm; p  0.008), a larger number of uncovered struts
17  16 vs. 8  11; p  0.03), smaller average SEI (0.89  0.04 vs. 0.92  0.03; p  0.001), and
reater average NUS (2.22  0.24 vs. 2.00  0.33; p  0.03). A signiﬁcant relationship existed be-
ween average SEI and average NUS (p  0.0001, R  0.68), and between average SEI and the num-
er of uncovered struts (p  0.0006, R  0.46). There was no signiﬁcant difference in major adverse
ardiac events during follow-up (median: 485 days, 7.1% vs. 12.8%; p  0.99).
onclusions Longer stents and greater asymmetric stent expansion may be important determinants
f thrombus formation after SES implantation. In this small cohort, the presence of thrombus did
ot increase the risk of major adverse cardiac events. (J Am Coll Cardiol Intv 2009;2:459–66)
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460lthough sirolimus-eluting stents (SES) have reduced the
ncidence of restenosis, late thrombosis, a life-threatening
omplication, has emerged as a major concern in the clinical
etting (1,2). Recent angioscopic analyses demonstrated that
he presence of subclinical thrombus in SES is more
ommon than the clinical incidence of stent thrombosis
3,4). Although several factors are reported as major pre-
ictors of clinical stent thrombosis (5), local determinants of
hrombus formation and its clinical significance under
ntiplatelet therapy are still unclear.
See page 467
Several studies have shown that asymmetric stent expan-
ion may affect the pattern of neointimal growth presumably
hrough uneven drug delivery (6,7). Because delayed arterial
ealing characterized by exposed stent struts is considered a
ossible risk for thrombosis (8), we hypothesized that
symmetric stent expansion could affect thrombus forma-
tion after SES implantation.
Thus, the purpose of the present
study was to assess the determi-
nants of thrombus formation 6
months after SES implantation
and its effect on long-term clin-
ical events using optical coher-
ence tomography (OCT).
Methods
Study population and methods.
Between October 2004 and Feb-
ruary 2008, 373 patients under-
went elective percutaneous coro-
ary intervention with SES (Cypher, Cordis Corp., Miami
akes, Florida) for de novo native coronary lesions (546 SES).
f the 258 patients (386 SES) who underwent 6-month
ollow-up coronary angiography, 67 patients were randomly
elected to receive 6-month follow-up OCT analysis. The
ercutaneous coronary intervention procedure for patients
nvolved in this study was performed with intravascular ultra-
ound (IVUS) guidance using a mechanical ultrasound trans-
ucer (Boston Scientific Corporation, Natick, Massachusetts)
r a dynamic-aperture ultrasound transducer (Volcano Corpo-
ation, Rancho Cordova, California).
All patients were taking aspirin 100 mg/day. Ticlopidine
00 mg/day or clopidogrel 75 mg/day were additionally
iven for at least 3 months after SES implantation. Clopi-
ogrel was not used until May 2006 because it had not been
pproved for clinical use in Japan before then. This study
as approved by the ethical committee of Kobe University,
nd all enrolled study patients gave their written informed
bbreviations
nd Acronyms
VUS  intravascular
ltrasound
SA  minimum stent area
US  neointimal
nevenness score
CT  optical coherence
omography
EI  stent eccentricity
ndex
ES  sirolimus-eluting
tent(s)onsent. puantitative coronary angiographic evaluation. Quantita-
ive angiographic parameters were calculated for the target
esion before and after the procedure and at the time of
ngiographic follow-up using dedicated software (QCA-
MS 5.1, Medis Imaging Systems, Leiden, the Nether-
ands). In-stent restenosis was defined as diameter stenosis
50% within the stented segment. In-stent late luminal loss
as defined as the difference between the minimal luminal
iameter immediately after the procedure and the minimal
uminal diameter at 6 months.
CT examination. An OCT examination was performed as
reviously reported (9). Briefly, a 0.016-inch OCT catheter
ImageWire, LightLab Imaging, Westford, Massachusetts)
as advanced to the distal end of the stented lesion through
n occlusion balloon catheter (Helios, LightLab Imaging).
o clear the blood from the field of view, the occlusion
alloon was inflated to 0.6 atm at the proximal site of the
ulprit lesion, and lactated Ringer’s solution was infused
nto the coronary artery from the distal tip of the occlusion
alloon catheter at 0.5 ml/s. The entire length of the stent
as automatically imaged at 1 mm/s.
CT analysis. All images were analyzed by an independent
bserver who was blinded to the clinical presentations and
esion characteristics. Cross-sectional OCT images were
nalyzed at 1-mm intervals (every 15 frames). Bifurcation
esions with major side branches were excluded from this
nalysis.
Neointimal thickness inside each SES strut was mea-
ured. Stent area and maximum and minimum stent diam-
ters were measured manually. Any SES struts with mea-
ured neointimal thickness equal to 0 m were defined as
ncovered struts. Maximum distance170 m between the
enter reflection of the strut and adjacent vessel surface was
efined as incomplete strut apposition (9). The frequency of
ncovered struts and incomplete strut apposition was cal-
ulated as the number of those struts divided by total struts
or each stent. To assess for stent asymmetric expansion, a
tent eccentricity index (SEI) was determined by the min-
mum stent diameter divided by the maximum stent diam-
ter in each cross section. For the assessment of the
nevenness of neointimal thickness, a neointimal uneven-
ess score (NUS) was calculated for each cross section as
aximum neointimal thickness in one cross section divided
y the average neointimal thickness of the same cross
ection (Fig. 1). Then, the average SEI and NUS were
alculated for each stent. Intracoronary thrombus was de-
ned as a protruding mass beyond the stent strut into the
umen with significant attenuation behind the mass (Fig. 2)
10,11). To differentiate thrombus from plaque protrusion
r neointimal hyperplasia, we excluded protruding masses
ithout significant signal attenuation and surface irregular-
ty. All stents involved in this study were divided into 2
roups (thrombus and nonthrombus) according to the
resence of thrombus detected by OCT. In addition,
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The white arrow points to an intracoronary thrombus.
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461ecause a minimum stent area (MSA) of 5.0 mm2 was
bserved in 80% of SES thrombosis cases according to a
revious study (12), we performed a subgroup analysis for
he subset of stents with MSA 5.0 mm2 to assess the
eterminants of thrombus formation in the absence of stent
nderexpansion.
ong-term clinical follow-up. Long-term (i.e., beyond
months) clinical follow-up data were obtained from
utpatient record reviews or telephone interviews. Major
dverse cardiac events were defined as a composite of death,
yocardial infarction, and target vessel revascularization.
arget vessel revascularization was defined as any reinter-
ention (surgical or percutaneous) to treat a luminal stenosis
ccurring in the same coronary vessel treated at the index
rocedure, within and beyond the target lesion limits. All
atients were followed up for a minimum of 6 months
median: 485 days) after the index procedure.
tatistical analysis. Statistical analysis was conducted with a
ommercially available software package (StatView 5.0,
AS Institute Inc., Cary, North Carolina). Continuous
ess: 0.09 mm. Maximum neointimal thickness: 0.11 mm. Neointimal uneven-
I): 3.15/3.19  0.99. Number of uncovered struts: 0. (B) A representative
um neointimal thickness: 0.11 mm. NUS: 0.11/0.04  2.75. Stent area: 6.59
ptical coherence tomography.Figure 1. OCT Measurements in Length and Area
(A) A representative image of symmetric stent expansion. Average neointimal thickn
ness score (NUS): 0.11/0.09  1.22. Stent area: 8.03 mm2. Stent eccentricity index (SE
image of asymmetric stent expansion. Average neointimal thickness: 0.04 mm. Maxim
2Figure 2. A Representative Image of Intracoronary Thrombusariables are presented as mean  SD. Differences in
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462ontinuous parameters between the 2 groups were calculated
sing an unpaired Student t test. Categorical variables were
resented using frequency counts, and intergroup compar-
sons were analyzed by Fisher exact test. Because every
ultiple stenting was performed with overlapping, statisti-
al analysis was performed on a patient (lesion) basis.
actors with a probability value 0.10 in univariate analysis
ere included in multivariate logistic regression analyses.
esults are reported with odds ratio (OR), 95% confidence
nterval (CI), and probability value. Simple correlations
etween the average SEI, average NUS, average neointimal
hickness, and the percentage and number of uncovered
truts were examined by Spearman correlation. A p value of
0.05 or less was considered to be statistically significant.
esults
f the 67 patients who received 6-month follow-up OCT
nalysis after SES implantation, we excluded 11 patients
ith incomplete image acquisition, 2 patients with left main
tenting, and 1 patient with SES fracture. Thus, 53 patients
53 lesions treated with 66 SES) were included in this study.
he average interval of follow-up OCT study was 190 days.
hrombus was identified in 14 patients (14 SES) by OCT.
herefore, the incidence of cases with thrombus was 26% in
ur study (thrombus: n  14 vs. nonthrombus: n  39).
aseline characteristics for these cases are shown in Table 1.
spirin was continued until follow-up for all SES and the
ercentage of dual antiplatelet therapy was similar. There
ere no significant differences in patient characteristics
etween the 2 groups (Table 1).
esion and procedural characteristics. Total stent length in
he thrombus group was significantly longer than that in the
onthrombus group. Otherwise, no significant differences
ere noted between the 2 groups with regard to angio-
Table 1. Patient Characteristics
Thrombus
(n  14)
Nonthrombus
(n  39) p Value
Age, yrs 69 9 68 9 0.71
Male 10 (72) 28 (71) 0.99
Hypertension 11 (75) 30 (67) 0.99
Diabetes 6 (43) 21 (54) 0.54
Smoking 3 (21) 13 (33) 0.51
Hyperlipidemia 9 (64) 27 (69) 0.75
Anginal status 0.36
Stable 11 (79) 35 (90)
Unstable 3 (21) 4 (10)
Chronic total occlusion 3 (21) 5 (13) 0.42
Follow-up, days 197 18 185 34 0.29
Dual antiplatelet therapy 8 (57) 17 (44) 0.53
Values are presented as mean SD or n (%).raphic and procedural characteristics (Table 2). aCT ﬁndings. In 1,271 cross-sectional images, 10,062 struts
ere identified. Mean stent area and MSA were similar
etween the 2 groups. There was no significant difference in
verage neointimal thickness. The thrombus group, how-
ver, had a larger number of uncovered struts, smaller
verage SEI, and greater average NUS (Table 3).
The relationship among the average SEI, average NUS,
nd number and frequency of uncovered struts are shown in
igure 3. For all of the 53 patients, a significant relationship
as found to exist between average SEI and average NUS.
n addition, average SEI was associated with the number
nd frequency of uncovered struts. There was no significant
orrelation between average SEI and average neointimal
hickness (Fig. 3).
Although this study is not powered to determine inde-
endent predictors for subclinical thrombus, multivariate
ogistic models showed that SEI (OR: 0.3; 95% CI: 0.10 to
.87; p  0.03) and stent length (OR: 1.07; 95% CI: 1.01
o 1.13; p  0.04) were associated with the presence of
hrombus in these patients. Variables tested included age,
ex, SEI, total stent length, and NUS.
ong-term clinical follow-up. Long-term clinical follow-up
ata (median: 485 days) after the index procedure were
btained for all patients involved in this study. No death or
yocardial infarction was observed, but 1 patient in the
hrombus group and 5 patients in the nonthrombus group
equired target vessel revascularization. All target vessel
evascularization events were related to in-stent or edge
estenosis of SES. There was no significant difference in
ajor adverse cardiac events during the follow-up period
thrombus: 7.1%, nonthrombus: 12.8%; p  0.99).
ubstudy: comparison within the stents with MSA of >5.0
m2. We detected 9 thrombus in 9 patients (9 SES) in the
ubset of 34 patients (42 SES) who had SES with an MSA
f 5.0 mm2. There were no significant differences in
emographics (age, sex, and coronary risk factors), proce-
ural, and lesion characteristics between the 2 groups. In
his subset, the thrombus group (n 9) showed greater SEI
han the nonthrombus group. Furthermore, a significant
elationship still existed between average SEI and average
US (p  0.0001, R  0.66), as well as between average
EI and the frequency (p  0.01, R  0.42) and numbers
p  0.05, R  0.34) of uncovered struts (Fig. 4).
iscussion
he present study demonstrated the following. 1) Throm-
us was detected in 14 out of 53 patients (26%) by OCT. 2)
he presence of thrombus following SES implantation was
ssociated with longer stent length, more frequent OCT
vidence of uncovered stent struts, asymmetric stent expan-
ion, and uneven neointimal thickness. A significant rela-
ionship existed between the average SEI and average NUS,
s well as between the average SEI and the number and
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463Table 2. Angiographic and Procedural Characteristics
Thrombus
(n  14)
Nonthrombus
(n  39) p Value
Vessel treated 0.48
LAD/RCA/LCX, % 29/42/29 46/36/18
Lesion location 0.75
Proximal 6 (43%) 14 (36%)
Mid/distal 8 (57%) 25 (64%)
AHA/ACC lesion classiﬁcation
A/B1/B2/C, % 14/21/43/22 13/39/31/17 0.69
Procedural characteristics
Total number of stents 1.4 0.5 1.2 0.4 0.18
Total stent length, mm 36.4 20.2 25.1 9.8 0.008
Stent diameter, mm 3.00 0.20 2.89 0.39 0.29
Maximum inﬂation pressure, atm 16 17 0.28
Final balloon size, mm 3.04 0.24 3.01 0.41 0.84
Post dilation 6 (43%) 21 (54%) 0.54
Multiple stenting, % 5 (36%) 7 (18%) 0.26
Debulking 2 (14%) 7 (18%) 0.99
Quantitative coronary angiography
Lesion length, mm 19.9 9.3 17.7 8.5 0.49
Reference diameter, mm 2.72 0.40 2.75 0.50 0.81
Minimum lumen diameter, mm
Before 0.50 0.44 0.75 0.52 0.12
After 2.12 0.36 2.33 0.54 0.19
Follow-up 1.98 0.47 2.08 0.50 0.51
% Diameter stenosis
Before 81.3 15.8 74.1 15.5 0.15
After 19.8 6.9 14.8 10.8 0.12
Follow-up 25.1 7.5 23.5 11.7 0.63
Acute gain, mm 1.62 0.56 1.50 0.70 0.57
Late loss, mm 0.14 0.44 0.24 0.36 0.41
Values are presented as mean SD or n (%).
ACC American College of Cardiology; AHA American Heart Association; LAD left anterior descending artery; LCX left circumflex artery;RCA right coronary artery.Table 3. Optical Coherence Tomography Measurements
Thrombus
(n  14)
Nonthrombus
(n  39) p Value
Average number of struts 232 131 174 103 0.10
Average number of incompletely apposed struts 9 10 5 7 0.11
Frequency of incompletely apposed struts, % 3.6 3.9 3.4 6.1 0.94
Average number of uncovered stent struts 17 16 8 11 0.03
Frequency of uncovered stent struts, % 8.0 5.1 6.1 8.3 0.43
Average stent area, mm2 7.34 1.41 7.56 2.04 0.72
Minimum stent area, mm2 5.67 1.63 6.04 2.06 0.54
Average neointimal thickness, m 74 44 70 49 0.82
Average SEI 0.89 0.04 0.92 0.03 0.001
Average NUS 2.22 0.24 2.00 0.33 0.03
Values are presented as mean SD or n (%).NUS neointimal unevenness score; SEI stent eccentricity index.
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Figure 3. Relationships Among OCT Parameters in Overall PatientsThe graphs show the relationships among OCT parameters to the overall patient population. Abbreviations as in Figure 1.0
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f
s
p
I
s
S
m
c
r
s
A
t
1
4
I
s
t
d
t
w
T
t
n
f
t
e
r
s
c
b
w
f
L
i
c
K
a
t
r
a
i
O
r
i
n
i
l
h
T
t
s
t
T
a
c
i
s
s
p
w
s
g
d
s
t
d
s
h
i
l
d
P
u
a
(
O
n
o
m
d
r
p
t
a
f
f
t
f
s
t
t
o
p
b
C
s
u
t
a
f
t
S
s
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 5 , 2 0 0 9 Otake et al.
MA Y 2 0 0 9 : 4 5 9 – 6 6 Determinants of Thrombus Formation After SES
465requency of uncovered stent struts. 3) There was no
ignificant increase in major adverse cardiac events in
atients with thrombus after SES implantation.
ncidence of the thrombus after SES implantation. In this
tudy, thrombus was detected in 14 out of 53 patients (66
ES). A 26% incidence rate of cases with thrombus at 6
onths may seem relatively higher than expected from the
linical incidence of SES thrombosis reported in the major
andomized trials (13–15). However, the results from our
tudy are comparable to previous angioscopic findings.
wata et al. (4) reported the incidence of thrombus forma-
ion as 30% (3 patients with thrombus of 10 patients) at 4,
0, and 21 months, and Takano et al. (16) reported it as
0% of patients at 6 months and 30% of patients at 2 years.
n our study, the incidence of subclinical thrombus was
imilar between patients who are taking only aspirin and
hose who are under dual antiplatelet therapy. Even under
ual antiplatelet therapy, a 30% to 40% rate of incidence of
hrombus formation has been reported and several cases
ith newly formed thrombus were also observed (4,16).
herefore, although dual antiplatelet therapy is an impor-
ant factor to reduce the risk of clinical thrombosis, it may
ot be effective enough to completely suppress thrombus
ormation after SES implantation.
Despite the relatively high incidence of thrombus forma-
ion after SES implantation, none of these patients experi-
nced thrombotic clinical events during the follow-up pe-
iod in our study or in previous studies. Additional factors
uch as antiplatelet resistance, intrinsic thrombogenicity, or
oronary flow dynamics might trigger clinical stent throm-
osis. Large-scale controlled studies are required to address
hether the presence of thrombus in SES could be a factor
or future clinical thrombosis or negative cardiac events.
ocal determinants on the presence of thrombus. Although
t is an infrequent complication, stent thrombosis is a
atastrophic event when it occurs. An angioscopic study by
otani et al. (3) demonstrated that thrombus formation was
ssociated with incomplete neointimal coverage that tended
o be more common in SES than in bare-metal stents. The
esults of our study and of the previous study are in
greement, showing that the presence of thrombus follow-
ng SES implantation was associated with more frequent
CT evidence of uncovered stent struts. In addition, our
esults showed that asymmetric stent expansion could be an
mportant factor in thrombus formation by increasing the
umber of uncovered struts and the heterogeneity of neo-
ntimal thickness, adding a new insight to previously pub-
ished studies. Within the same SES, some struts showed
ealing as neointimal coverage but others remain uncovered.
hese uncovered struts may serve as a nidus for mural
hrombus formation. A recent human autopsy study (8) has
hown that the existence of uncovered struts without endo-
helialization is a common finding of late stent thrombosis.
herefore, we speculate that asymmetric stent expansion affects thrombus formation in part due to uneven stent
overage and healing.
The mechanisms by which SES induce nonuniform
ncomplete healing are not fully understood. Various factors
uch as lesion characteristics (17), drug distribution, and
trut apposition (7) are considered to be involved. One
ossible mechanism is uneven drug delivery to the vessel
all due to asymmetric stent expansion. It has already been
hown that local drug concentrations and concentration
radients are inextricably linked to the biological effect of a
rug (7). Hwang et al. (7) have shown that inhomogeneous
trut placement dramatically affects local drug concentra-
ions without changing mean concentrations. Therefore,
rug concentration gradients resulting from nonuniform
trut distribution may lead to nonuniform healing. This
ypothesis may be supported by a study of Finn et al. (18),
n which a delayed healing process was exhibited by over-
apping stent segments when compared with proximal and
istal nonoverlapping segments in animals.
erformance of OCT. In a previous study where IVUS was
sed, asymmetric stent expansion did not seem to affect the
verage neointimal hyperplasia area after SES implantation
19), similar to the findings in our study (Fig. 3). However,
CT provided more detailed analysis on the condition of
eointimal growth as shown in this study.
Although IVUS is a robust tool for the quantification
f neointima, the resolution of IVUS (100 to 150 m)
ay not be sufficient for detecting a suppressed, small
egree of neointimal hyperplasia (19). As previously
eported (9), the median thickness of neointimal hyper-
lasia after SES implantation is less than IVUS resolu-
ion. Because OCT is an imaging modality with high
xial resolution (10 to 20 m), it is a tool most suitable
or the visualization of lumen/stent surfaces, especially
or measuring suppressed neointima after SES (9). Op-
ical coherence tomography is also a powerful modality
or evaluation of thrombus in vivo. Histology-controlled
tudies have shown that the resolution of OCT can detect
he microstructure of atherosclerotic plaque including
hrombus (11,20). In a recent study comparing the ability
f OCT, IVUS, and angioscopy to assess coronary
laque, OCT was able to visualize intracoronary throm-
us as clearly as coronary angioscopy (21).
linical implications. The observations from this study have
everal potentially important clinical implications. Stent
nderexpansion was reported to be associated with SES
hrombosis (12). On the other hand, our results suggest that
symmetric stent expansion may contribute to thrombus
ormation even in stents with an MSA 5.0 mm2. Al-
hough bigger-is-better strategy is not critically important in
ES implantation compared with bare-metal stenting (22),
tent symmetry could be important for the reduction of
hrombus formation regardless of MSA. Intravascular im-
ging technologies such as IVUS and OCT can still play an
i
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466mportant role to optimize stenting in the era of drug-
luting stents.
tudy limitations. Several limitations should be noted in
his study. First, this study was based on a relatively small
ample size, raising the possibility of selection bias.
lthough we performed multivariate analysis, this study
s not sufficiently powered to detect independent predic-
ors for subclinical thrombus. Second, angioscopy, con-
idered the gold standard for thrombus detection, and
erial OCT analysis were not performed in this study.
herefore, there is a question of whether the protruding
asses were in fact thrombus. An angioscopy-controlled
tudy or serial OCT analysis will be required to further
onfirm our results. Third, this study only examined SES
ithout any comparison with bare-metal stents and other
rug-eluting stents. Finally, the study design was obser-
ational; therefore, it is still unclear whether additional
nterventions to acquire optimal stent expansion could
urther reduce the incidence of thrombus formation in
atients receiving SES.
onclusions
n this OCT study, longer stent length and greater asym-
etric stent expansion were found to be determinants of
hrombus formation following SES implantation. Asym-
etric stent expansion may interfere with even neointimal
overage of the stent surface after SES deployment; uneven
eointimal coverage is perhaps a key mechanism for throm-
us formation. The implications of this study suggest the
linical utility of additional imaging modalities to ensure
hat intracoronary stents are properly and fully deployed so
atients are not subjected to the risk of future thrombus
ormation.
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